Latent Tuberculosis Infection Clinical Trial
Official title:
A Multicenter, Randomized, Double-blind, Controlled Phase Ⅲ Trial of Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) for the Diagnosis of Mycobacterium Tuberculosis Infection in 65-year-olds and Above
A multicenter, randomized, blind, controlled trial design was used to select 240 tuberculosis (TB) patients, 120 non-tuberculous community population with other lung diseases, and 420 healthy community population without other lung diseases who met the inclusion criteria of this study. Blood supply specific gamma-interferon (T-SPOT) detection was performed first. Then, EC and Purified Protein derivation of tuberculin (TB-PPD) skin tests were performed on both arms, and the recorded results were observed. The first 24 cases of TB patients, the first 12 cases of non-tuberculous community population with other lung diseases, and the first 42 cases of healthy community population without other lung diseases were included in the trial subgroup. Physical examination, blood routine, urine routine, liver and kidney function, and electrocardiogram tests were required before and 7 days after skin test after study number assignment.
A multicenter, randomized, blind, controlled trial design was adopted in this study. Subjects were enrolled in this clinical study after being qualified by physical examination, vital signs detection (body temperature, blood pressure, pulse and respiration), chest imaging (DR/CT) examination, mycobacterium tuberculosis etiology examination, HIV antibody detection, fasting blood glucose detection, etc. A total of 240 TB patients, 120 non-tuberculous community people with other lung diseases, and 420 healthy community people without other lung diseases were selected for inclusion in this study. Blood samples were collected for specific gamma-interferon (T-SPOT) detection, and then EC and TB-PPD in the same double arm skin test were used to observe and record the results. The first 24 cases of TB patients, the first 12 cases of non-tuberculous community population with other lung diseases, and the first 42 cases of healthy community population without other lung diseases were included in the trial subgroup. Physical examination, blood routine, urine routine, liver and kidney function, and electrocardiogram tests were required before and 7 days after skin test after study number assignment. Vital signs (body temperature, blood pressure, pulse and respiration) were measured 30min and 24h after skin test, and body temperature was measured 48h and 72h after skin test. The skin reaction at the injection site was observed at 0min, 24h, 48h and 72h after skin test. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04094012 -
Risk of SDRs Under 3HP and 1HP Regimen for LTBI
|
Phase 3 | |
| Completed |
NCT01582711 -
Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT
|
Phase 3 | |
| Recruiting |
NCT06033807 -
Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients
|
||
| Completed |
NCT01622140 -
Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis
|
||
| Completed |
NCT00557765 -
Use of a Gamma-IFN Assay in Contact Tracing for Tuberculosis in a Low-Incidence, High Immigration Area
|
N/A | |
| Completed |
NCT00463086 -
Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons
|
N/A | |
| Active, not recruiting |
NCT01398618 -
Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI)
|
Phase 3 | |
| Recruiting |
NCT00905970 -
Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection
|
N/A | |
| Recruiting |
NCT00449345 -
Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis
|
N/A | |
| Completed |
NCT02641106 -
VDOT for Monitoring Adherence to LTBI Treatment
|
N/A | |
| Completed |
NCT00804713 -
Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits
|
N/A | |
| Completed |
NCT01136161 -
Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection
|
Phase 2 | |
| Recruiting |
NCT03312647 -
Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection
|
N/A | |
| Completed |
NCT02810678 -
Enhancing the Public Health Impact of Latent Tuberculosis (TB) Infection Diagnosis and Treatment
|
N/A | |
| Completed |
NCT01223534 -
QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.
|
Phase 4 | |
| Withdrawn |
NCT00558480 -
Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis
|
N/A | |
| Recruiting |
NCT00692809 -
Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infection
|
N/A | |
| Completed |
NCT03702049 -
Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV
|
N/A | |
| Terminated |
NCT01761201 -
"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients".
|
Phase 3 | |
| Completed |
NCT01608685 -
Interferon Gamma Release Assays (IGRA) Testing Versus Tuberculin Skin Test in Renal Transplant Recipients
|
N/A |